Cannabics Pharmaceuticals Inc (OTCQB: CNBX), a company involved in personalised cannabinoid based cancer medicine, announced yesterday that it has named Itamar Borochov as its new director and member of its board.
Borochov is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies that operate in regulated markets. He was the original founder of Cannabics Pharmaceuticals Inc.
Eyal Barad, CEO and co-founder, said, 'The entire team is pleased to have Itamar return to the board at a very significant time, and I am sure his intimate knowledge and industry experience will significantly contribute to the company as we move into our next planned phases.'
CStone announces Phase I CS2009 data at ESMO 2025
Antengene reveals ATG-022 clinical data at ESMO 2025
Sichuan Kelun-Biotech presents positive Phase 3 trial results for sac-TMT
Clarity Pharmaceuticals signs copper-67 supply agreement with Nusano
SOPHiA DDM Digital Twins launched to simulate patient outcomes and support oncology decisions
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Privo Technologies reports progress in oral cancer trial
Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference